Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC

NCT03084250 is registered in ClinicalTrials.gov with Shanghai Nanhui Nanhua Hospital as lead sponsor.

NCT NCT03084250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03084250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
Lead sponsor
Shanghai Nanhui Nanhua Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
March 10, 2017
Completion date
December 1, 2023
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b